CLEVELAND, May 13, 2015 /PRNewswire/ -- DATATRAK
International, Inc. (OTCQX: DTRK), a leader in cloud-based,
unified eClinical® technologies and related
services for the clinical trials industry, today announced its
operating results for the first quarter 2015.
First Quarter Highlights:
- Fourth consecutive quarter of record breaking backlog, ending
the quarter (March 31, 2015) at
$27.8 million, a 7% increase over
backlog at the end of 2014
- New contract sales increased 35% year-over-year, the result of
continued investments in the Sales and Marketing functions over the
years to improve execution and drive new contracts
- Book-to-bill ratio of 2.6 at end of First Quarter 2015, up from
Year End 2014, reflecting the continued transition to a longer more
stable revenue stream by signing more Enterprise Agreements and
large platform wins
- DATATRAK Chicago office
opened in April 2015 expanding
presence in leading life sciences market
- DATATRAK expertise featured at industry events in
Japan and Belgium on topics of adopting time saving
eSource data collection methodology and technology trends affecting
clinical research
- DATATRAK challenged clinical research
professionals to reconsider technology applications and simplify
processes at key industry events for the period, including DIA
Japan, Outsourcing in Clinical Trials, SCOPE Summit, and ACDM
Laurence P. Birch, Chairman and
CEO, commented "Research professionals are recognizing that
DATATRAK can simplify and simultaneously improve the
management of data, including gaining critical insight to their
research through our industry-leading reporting
functionality. Using DATATRAK products, clients
have achieved time and cost savings, reporting efficiencies, and
quality improvements that other companies promise but we
deliver."
Birch went on to say, "The success we're seeing in new contract
sales is a positive for the business overall. New clients often
become our most dedicated partners, setting the stage for future
revenue growth. Clients who choose our solutions often expand their
usage after experiencing, first hand, the ease of use and unequaled
data analysis tools for C Suite executives of our client
companies.
We are excited that our strategy of developing long term, multi
trial engagements is paying off in rapidly increasing
backlog. Though these agreements tend to slow short term
revenue growth, they secure future revenue allowing our sales team
to build new long term relationships, ultimately leading to
accelerating revenue. Our book to bill ratio has risen from
1.5 to 2.6 since 2011 providing a much more secure foundation for
growing our business.
Additionally, as we have successfully defended our patent with
the USPTO, we have begun to see rising litigation costs as we
continue to pursue our various claims against Medidata."
Birch concluded, "Complexities that are often viewed as a
necessary evil in some solutions can be avoided. The reality is
research professionals don't have to accept complicated mid-study
changes and long wait times for reporting. We will continue to
challenge the clinical research industry to rethink their software
choices and look forward to showing them how much time and money
they can save with DATATRAK."
Financial Highlights:
The Company's revenue decreased 7% for the three months ended
March 31, 2015 compared to the three
months ended March 31, 2014.
The decrease in revenue is due to the extension of an enterprise
license agreement, which required DATATRAK to recognize the
new contract revenue over a longer period of time, affecting
short-term revenue, and the tapering off of a significant long-term
contract that is nearing completion. DATATRAK is
evolving the focus of its sales model to enhance long-term
stability through enterprise license agreements. The change
in focus affects revenue growth in the short-term as evidenced by
the decrease for the first quarter of 2015; however, it is
establishing long-term stability as evidenced by the increase in
backlog. Direct costs increased by 10% during this same time
period as a result of salary adjustments and efforts to support
DATATRAK's clinical and consulting services business by
hiring to scale to support the growth of the organization.
The Company's gross margin decreased to 77% for the first quarter
of 2015 compared to 81% for the first quarter of 2014 due to lower
revenue and higher direct costs, as mentioned above. SG&A
expenses increased by $463,000, or
19%, to $2,898,000 from $2,435,000 for the three months ended
March 31, 2015 and 2014,
respectively. The increase was primarily due to higher legal costs,
a substantial portion related to patent defense, and equipment
expenses. These increases were partially offset by a decline
in consulting costs due to several initiatives that took place in
2014 to support sales, technical services and quality
assurance. As a result, DATATRAK's loss from
operations for three months ended March 31,
2015 was $(1,015,000) compared
to a loss from operations of $(287,000) for the corresponding period in
2014.
DATATRAK's backlog at March 31,
2015 was $27.8 million
compared to a backlog of $26.0
million at December 31, 2014.
Backlog consists of future value from authorization letters to
commence services, statements of work, technology and services
agreements, change orders and other customer contracts, billed and
unbilled. The improvement in backlog was due to new contract sales,
in particular enterprise agreements, change orders and contract
expansions.
All contracts are subject to possible delays or cancellation or
can change in scope in a positive or negative direction. Therefore,
current backlog is not necessarily indicative of the Company's
future quarterly or annual revenue. Historically, backlog has been
a poor predictor of the Company's short-term revenue.
Join DATATRAK Thought Leaders:
- Twitter
- LinkedIn
- SlideShare
- The DATATRAK Blog
Tweet: Q1 2015 results include 4th consecutive
quarter with backlog growth and 35% growth in new contracts
http://bit.ly/1bPvrXA
About DATATRAK International,
Inc.
DATATRAK International is a worldwide technology
and services company delivering unified
eClinical® solutions and related services for the
clinical trials industry. DATATRAK built its
multi-component, comprehensive solution on a single, unified
platform and expanded this concept to include services delivery via
DATATRAK's Clinical and Consulting Services group. The
Company delivers a complete portfolio of software products designed
to accelerate the reporting of clinical research data from sites to
sponsors and ultimately regulatory authorities, faster and more
efficiently than loosely integrated technologies. The
DATATRAK ONE® software solution, deployed
worldwide through an ASP or Enterprise Transfer offering, supports
Preclinical and Phase I - Phase IV drug and device studies in
multiple languages throughout the world. DATATRAK is located
in Chicago, Illinois; Cleveland, Ohio; Bryan, Texas; Cary (RTP), North Carolina; and Plymouth, Minnesota. For more
information, visit http://www.datatrak.com.
Except for the historical information contained in this press
release, the statements made in this release are forward-looking
statements. These forward-looking statements
are made based on management's expectations, assumptions, estimates
and current beliefs concerning the operations, future results and
prospects of the Company and are subject to uncertainties and
factors which are difficult to predict and, in many instances, are
beyond the control of the Company, and which could cause actual
results to differ materially from those contemplated in these
forward-looking statements. For a list of certain factors that may
cause actual results to differ materially from those contemplated
in these forward looking statements, please see the Company's
report filed with the OTCQX Market on March
13, 2015 announcing its results for the full-year period
ended December 31, 2014. The Company
undertakes no obligation to update publicly or revise any
forward-looking statement whether as a result of new information,
future events or otherwise.
DATATRAK
International, Inc. and Subsidiaries Condensed
Consolidated Balance Sheet Data
(Unaudited)
|
|
March 31,
2015
|
December 31,
2014
|
Cash and cash
equivalents
|
$2,079,022
|
$3,510,499
|
Certificate of
deposit
|
300,261
|
300,000
|
Accounts receivable,
net
|
1,155,199
|
1,143,045
|
Property &
equipment, net
|
546,063
|
508,895
|
Other
|
592,457
|
722,711
|
Total
assets
|
$4,673,002
|
$6,185,150
|
|
|
|
Accounts payable and
other current liabilities
|
$1,504,447
|
$1,900,258
|
Deferred
revenue
|
5,625,642
|
6,170,711
|
Other long-term
liabilities
|
55,759
|
67,701
|
Shareholders' deficit
|
(2,512,846)
|
(1,953,520)
|
Total
liabilities and shareholders' deficit
|
$4,673.002
|
$6,185.150
|
|
|
|
DATATRAK
International, Inc. and Subsidiaries
Condensed
Consolidated Statements of Operations
(Unaudited)
|
|
For the 3 Months
Ended March 31,
|
|
2015
|
2014
|
Revenue
|
$2,489,492
|
$2,674,488
|
Direct
costs
|
565,099
|
512,604
|
Gross
profit
|
1,924,393
|
2,161,884
|
|
|
|
Selling, general and
administrative expenses
|
2,897,958
|
2,434,615
|
Depreciation and
amortization
|
41,605
|
14,730
|
Loss
from operations
|
(1,015,170)
|
(287,461)
|
|
|
|
Interest
income
|
503
|
349
|
Interest
expense
|
(3,449)
|
(2,922)
|
Net
loss
|
$(1,018,116)
|
$
(290,034)
|
Net loss per
share:
|
|
|
Net loss per share, basic and diluted
|
$
(0.70)
|
$
(0.21)
|
Weighted-average shares outstanding, basic and diluted
|
1,462,297
|
1,411,186
|
|
|
|
|
|
|
|
|
|
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/datatrak-international-inc-reports-first-quarter-results-of-2015-300082901.html
SOURCE DATATRAK International, Inc.